Meeting the UK demand for COVID19/SARS-CoV-2 vaccines via integrated manufacturing and supply chain optimisation

通过集成制造和供应链优化满足英国对 COVID19/SARS-CoV-2 疫苗的需求

• 批准号: EP/V01479X/1
• 负责人: Nilay Shah
• 金额: $ 57.1万
• 依托单位: Imperial College London
• 依托单位国家: 英国
• 项目类别: Research Grant
• 财政年份: 2020
• 资助国家: 英国
• 起止时间: 2020 至 无数据
• 项目状态: 已结题
• 来源: https://gtr.ukri.org/projects?ref=EP%2FV01479X%2F1
• 关键词: Meeting; UK; demand; COVID19; SARS

With the world's exit strategy from the current Covid-19 pandemic dependent on developing herd immunity through mass vaccination, there is imminent need to develop a roadmap for vaccine rapid manufacture and distribution at unprecedented scale. We seek funding to develop a blueprint for ramping up production, distribution and administration of SARS-CoV-2 vaccines based on a stratified vaccination strategy that starts with front-line personnel all the way to mass vaccination of the general UK population. To do this, we will combine process modelling with supply-chain optimisation to ensure (a) drug product and final drug substance availability, and (b) that production goes hand-in-hand with immediate availability for progressively larger parts of the population. Our models will be open-source and publicly available, and they will subsequently be extended to describe European manufacturing capabilities and vaccination campaigns. We are members of both the UCL-Oxford VaxHub and Imperial's Future Vaccine Manufacturing Hub (FVMH) and have had early access to data for the viral vector vaccine developed by the Jenner Institute and the saRNA vaccine developed by the Shattock group. As such,we have already developed manufacturing models and have been working on optimisation and scaling up strategies. With these two technologies being the global frontrunners in the race to clinical trials (e.g. Moderna in the USA is in Phase I clinical trials, NCT04283461 and Curevac in Germany is aiming to enter clinical trials in early summer 2020), our models will be applicable to any of these vaccines that receive regulatory approval.

随着世界摆脱当前新冠肺炎大流行的战略依赖于通过大规模接种发展群体免疫，迫切需要制定一项路线图，以前所未有的规模快速制造和分发疫苗。我们寻求资金，以制定一份蓝图，以加强SARS-CoV-2疫苗的生产、分销和管理，该蓝图基于分层接种战略，从一线人员一直到英国普通人口的大规模接种。为此，我们将把流程建模与供应链优化相结合，以确保(A)药品产品和最终药品的可用性，以及(B)生产与即时供应齐头并进，以满足越来越多的人口。我们的模型将是开源和公开可用的，它们随后将被扩展到描述欧洲的制造能力和疫苗接种活动。我们是UCL-Oxford VaxHub和Imperial的未来疫苗制造中心(FVMH)的成员，并已及早获得了Jenner研究所开发的病毒载体疫苗和Shattock小组开发的Sarna疫苗的数据。因此，我们已经开发了制造模式，并一直在努力优化和扩大战略。由于这两项技术在临床试验竞赛中处于全球领先地位(例如，美国的莫德纳正在进行I期临床试验，德国的NCT04283461和德国的CureVac计划于2020年初夏进入临床试验)，我们的模型将适用于任何获得监管部门批准的疫苗。

项目成果

Stability Modelling of mRNA Vaccine Quality Based on Temperature Monitoring throughout the Distribution Chain.

• DOI: 10.3390/pharmaceutics14020430
• 发表时间: 2022-02-17
• 期刊: Pharmaceutics
• 影响因子: 5.4
• 作者: Kis Z

Pandemic-response adenoviral vector and RNA vaccine manufacturing.

• DOI: 10.1038/s41541-022-00447-3
• 发表时间: 2022-03-02
• 期刊: NPJ vaccines
• 影响因子: 9.2
• 作者: Kis Z;Tak K;Ibrahim D;Papathanasiou MM;Chachuat B;Shah N;Kontoravdi C
• 通讯作者: Kontoravdi C

Novel drug-target interactions via link prediction and network embedding.

• DOI: 10.1186/s12859-022-04650-w
• 发表时间: 2022-04-04
• 期刊: BMC bioinformatics
• 影响因子: 3
• 作者: Amiri Souri E;Laddach R;Karagiannis SN;Papageorgiou LG;Tsoka S
• 通讯作者: Tsoka S

Model-Based Planning and Delivery of Mass Vaccination Campaigns against Infectious Disease: Application to the COVID-19 Pandemic in the UK.

基于模型的计划和针对传染病的大规模疫苗接种运动：在英国的COVID-19大流行中的应用。

• DOI: 10.3390/vaccines9121460
• 发表时间: 2021-12-10
• 期刊: Vaccines
• 影响因子: 7.8
• 作者: Ibrahim D;Kis Z;Tak K;Papathanasiou MM;Kontoravdi C;Chachuat B;Shah N
• 通讯作者: Shah N

Quality by design modelling to support rapid RNA vaccine production against emerging infectious diseases.

• DOI: 10.1038/s41541-021-00322-7
• 发表时间: 2021-04-29
• 期刊: NPJ vaccines
• 影响因子: 9.2
• 作者: van de Berg D;Kis Z;Behmer CF;Samnuan K;Blakney AK;Kontoravdi C;Shattock R;Shah N
• 通讯作者: Shah N